海西新药已通过港交所上市聆讯,华泰国际和招银国际为其联席保荐人。 公司是一家商业化阶段的制药企业,拥有研发、生产和销售能力,并有在研创新药管线。公司已获批14款仿制药,并拥有四款在研创新药。商业化产品组合涵盖消化系统、心血管系统、内分泌系统、神经系统及炎症疾病领域的仿制药。 公司采用仿制药和在研创新药的双轨业务模式。四款仿制药入选国家带量采购(VBP)计划,并持续贡献大量收益。 2024年,...
Source Link海西新药已通过港交所上市聆讯,华泰国际和招银国际为其联席保荐人。 公司是一家商业化阶段的制药企业,拥有研发、生产和销售能力,并有在研创新药管线。公司已获批14款仿制药,并拥有四款在研创新药。商业化产品组合涵盖消化系统、心血管系统、内分泌系统、神经系统及炎症疾病领域的仿制药。 公司采用仿制药和在研创新药的双轨业务模式。四款仿制药入选国家带量采购(VBP)计划,并持续贡献大量收益。 2024年,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.